(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2011 (24.03.2011)

PCT

(10) International Publication Number
WO 2011/033375 A2

(51) International Patent Classification:
C12N 15/90 (2006.01) *C12N 15/113* (2010.01)

(21) International Application Number:
PCT/IB2010/002337

(22) International Filing Date:
20 September 2010 (20.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/243,950 18 September 2009 (18.09.2009) US

(71) Applicant *(for all designated States except US)*: **SELEXIS S.A.** [CH/CH]; 18, Chemin des Aulx, 1228 Plan-les-Ouates (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MERMOD, Nicolas** [CH/CH]; c/o Selexis S.A., 18, Chemin des Aulx, 1228 Plan-les-Ouates (CH). **GIROD, Pierre-Alain** [CH/CH]; c/o Selexis S.A., 18, Chemin des Aulx, 1228 Plan-les-Ouates (CH). **GRANDJEAN, Mélanie** [CH/CH]; c/o Selexis S.A., 18, Chemin des Aulx, 1228 Plan-les-Ouates (CH). **LE FOURN, Valérie** [CH/CH]; c/o Selexis S.A., 18, Chemin des Aulx, 1228 Plan-les-Ouates (CH). **CALABRESE, David** [CH/CH]; c/o Selexis S.A., 18, Chemin des Aulx, 1228 Plan-les-Ouates (CH). **REGAMEY, Alexandre** [CH/CH]; c/o Selexis S.A., 18, Chemin des Aulx, 1228 Plan-les-Ouates (CH).

(74) Agent: **IPRIS GMBH**; PO Box 445, Pelikanweg 2, CH-4003 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: PRODUCTS AND METHODS FOR ENHANCED TRANSGENE EXPRESSION AND PROCESSING

Fig. 1C



(57) **Abstract**: Disclosed are methods and eukaryotic host cells for transgene expression. The cells may be treated and/or modified to increase homologous recombination (HR), decrease non homologous end joining (NHEJ) and/or to enhanced a HR/NHEJ ratio in said cell. Such cells can be transfected with vectors comprising the transgene, which advantageously integrates into the genome of the cell to form a concatemeric strucutre which may comprise more than 200 transgene copies. Certain expression enhancing elements such as MARs are advantageously provided to further enhance and/or facilitate transgene expression. Disclosed is also a recombinant eukaryotic host cell, in particular a non-primate host cell, comprising a transgenic sequence encoding a protein and/or a RNA, in particualr a primate protein and/or RNA, involved in translocation across the ER membrane and/or secretion across the cytoplasmic membrane.

WO 2011/033375 A2